At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 240 enrolled
Drug / intervention
Galcanezumab 300 mg +1 moredrug
Likely dose
Galcanezumab 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of : Galcanezumab (LY2951742) With a Long-Term Open-Label Extension in Patients With Chronic Cluster Headache
In Brief
A Phase 3 clinical trial evaluating Galcanezumab 300 mg and Placebo for Chronic Cluster Headache. Completed, enrolled 240 participants across 48 sites in 12 countries.
Detailed Summary
The main purpose of this study is to evaluate the efficacy of the study drug known as galcanezumab in participants with chronic cluster headache.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Cluster Headache
CountriesBelgium, Canada, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedMay 2015
Enrollment StartJun 2015
Primary CompletionMar 2018
Study CompletionAug 2019
TodayJul 2026
First PostedMay 8, 2015
Enrollment StartJun 18, 2015
Primary CompletionMar 27, 2018
Study CompletionAug 14, 2019
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 11.2 years ago
Interventions
Galcanezumab 300 mgdrug
Administered SC
Placebodrug
Administered SC